Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease

Although there were only 7 patients with FGFR2 fusion in our trial, none of whom had an objective response, we note that the disease control rate in this group was 71%, which is similar to that in the overall trial population.Having said that, more information is needed to understand the clinical benefit of erdafitinib both in patients with no history of chemotherapy and in those with FGFR alterations.